News

In the wake of unexpectedly positive clinical results from a trial testing the folfirinox chemotherapy regimen in patients with pancreatic cancer, after surgery, Targovax ASA has decided to drop development of its therapeutic vaccine for this indication.

Emulate Inc, the developer of micro-engineered chips that mimic that activity of live human organs, has raised $36 million in a Series C financing round to finance the expansion of its organs-on-chips technology that is being used by the pharma industry to test candidate drugs for saf

Roche and Foundation Medicine Inc reached a definitive merger agreement on 19 June enabling the Swiss multinational to acquire shares of the US molecular information company that it does not already own.

Syncona Investment Management Ltd of the UK has launched two new gene therapy companies to complement its existing portfolio which includes Nightstar Therapeutics Plc and Freeline Therapeutics Ltd.

A gene therapy for a rare, genetic eye disorder has been selected by the US Food and Drug Administration for its Regenerative Medicine Advanced Therapy Designation in recognition of the product’s potential to treat an unmet medical need.

The European Medicines Agency is restricting the use of two checkpoint inhibitor drugs as first-line treatments for urothelial cancer, or cancer of the bladder and urinary tract, because they may not work as well as chemotherapy in this group of patients.

The US Food and Drug Administration has approved the marketing of an artificial intelligence algorithm which is part of a diagnostic intended to help physicians detect wrist fractures.

Two Phase 3 trials of the candidate Alzheimer’s drug lanabecestat have been stopped for futility, Eli Lilly and Company and AstraZeneca Plc announced on  12 June.

A short 18 months after its launch as a new company, Microbiotica Ltd has entered into a multi-year collaboration with Genentech, a member of the Roche group, to discover, develop and commercialise biomarkers, targets and medicines for inflammatory bowel disease (IBD). 

Hookipa Biotech AG has signed a licencing deal with Gilead Sciences Inc giving the US company exclusive rights to its technology platform to develop vaccines targeting the  hepatitis B and the human immunodeficiency viruses. The agreement brings Austria-based